57
Participants
Start Date
January 25, 2018
Primary Completion Date
October 28, 2019
Study Completion Date
July 23, 2020
EBR/GZR FDC Tablet
Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
Placebo
Placebo tablet matched to EBR/GZR FDC tablet.
Grazoprevir Oral Granules
Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
Elbasvir Oral Granules
Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
Children's Hospital of Pittsburgh ( Site 0024), Pittsburgh
Children's Center for Advanced Pediatrics ( Site 0204), Atlanta
Medizinische Hochschule Hannover Kinderklinik K10 ( Site 0105), Hanover
Florida Hospital ( Site 0006), Orlando
Helios Klinikum Wuppertal GmbH ( Site 0104), Wuppertal
Cincinnati Children's Hospital Medical Center ( Site 0003), Cincinnati
American Research Corporation ( Site 0200), San Antonio
Klinikum Starnberg ( Site 0107), Starnberg
University of California San Francisco ( Site 0020), San Francisco
Children's Hospital and Regional Medical Center ( Site 0017), Seattle
Children's Hospital Boston ( Site 0009), Boston
WSOZ im.T.Browicza w Bydgoszczy ( Site 0800), Bydgoszcz
Wojewodzki Specjalistyczny Szpital im. dr W. Bieganskiego w Lodzi ( Site 0810), Lodz
MED-POLONIA Sp. z o.o. ( Site 0808), Poznan
Karolinska Universitetssjukhuset Huddinge. ( Site 0062), Stockholm
Merck Sharp & Dohme LLC
INDUSTRY